Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis

J Neurol. 2017 Jan;264(1):168-169. doi: 10.1007/s00415-016-8306-x. Epub 2016 Nov 25.

Authors

María Rosario Blasco¹, Antonio Ramos², Celia García Malo², Antonio García-Merino²

Affiliations

¹ Hospital Universitario Puerta de Hierro-Majadahonda, Manuel de Falla 1, Majadahonda, 28222, Madrid, Spain. [email protected].
² Hospital Universitario Puerta de Hierro-Majadahonda, Manuel de Falla 1, Majadahonda, 28222, Madrid, Spain.

PMID: 27888417
DOI: 10.1007/s00415-016-8306-x

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Alemtuzumab
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Diagnosis, Differential
Female
Humans
Immunologic Factors / adverse effects*
Immunologic Factors / therapeutic use
Multiple Sclerosis, Relapsing-Remitting / complications
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Pericarditis / chemically induced*
Pericarditis / diagnostic imaging
Pericarditis / therapy
Pneumonia / chemically induced*
Pneumonia / diagnostic imaging
Pneumonia / therapy

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
Alemtuzumab